Diaz Mora Prameyllawati on Going Beyond the Price Tag for Gene Therapies in Hemophilia
Diaz Mora Prameyllawati, PhD Candidate at Erasmus MC, shared on LinkedIn:
”Beyond the price tag of gene therapy
Gene therapies are often discussed in terms of their high price, which can range from €1 to €3.5 million per individual.
In our latest study on gene therapy for hemophilia, we went beyond the price tag and focused on what it actually takes to deliver these therapies in clinical practice.
To support successful and sustainable implementation, we developed:
- A detailed process map covering all care activities from site preparation to follow-up.
- Comprehensive cost catalogs capturing every component of care, enabling other hospitals and countries to estimate their own delivery costs.
These tools aim to inform economic evaluations, reimbursement discussions, and the real-world implementation of gene therapy for hemophilia.
More details in our latest publication.
This work was made possible through the support of the SYMPHONY consortium.
I sincerely thank all participating healthcare professionals for their openness and valuable insights during the interviews, as well as my supervisors and co-authors for their guidance and collaboration throughout the study.”
Read the full article here.
Article: Health care resources and costs associated with delivering gene therapy for hemophilia in clinical practice
Authors: Diaz M. Prameyllawati, Caroline M.A. Mussert, Martijn A.H. Oude Voshaar, Hester F. Lingsma, Marjon H. Cnossen, Michiel Coppens, Karina Meijer, Paul R. van der Valk, Frank W.G. Leebeek, Renske M.T. ten Ham
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 17, 2026, 02:00How Antiphospholipid Syndrome Can Affect the Adrenal Glands – APS Foundation of America
-
Oct 17, 2026, 01:59Liza-Marie Johnson: How Far Should Clinicians Go to Influence Parents’ Decisions?
-
Oct 17, 2026, 01:54Jim Hoffman: The Importance of Self-Advocacy and Understanding Autoimmune Mechanisms
-
Oct 17, 2026, 01:53Kristopher Jonas: Listening to Patients and Recognizing the Donors Who Make Treatment Possible
-
Oct 16, 2026, 18:12Adil Nawaz: Extended Dual Antiplatelet Therapy After Coronary Stenting
-
Oct 16, 2026, 17:50Elad Asher։ STORM-PE Shows Functional Benefits of Thrombectomy
-
Oct 16, 2026, 17:32Shruthi Narayan: STORM-PE and STRIKE-PE Studies Advance Understanding of Recovery After Pulmonary Embolism
-
Oct 16, 2026, 17:22Wolfgang Miesbach։ What a Near-Perfect FISH Score Fails to See
-
Oct 16, 2026, 17:06Troels Wienecke: Connecting Myeloproliferative Disease and Ischemic Stroke